Publications & Posters
Scholary publications
Immuno-Oncology
SRK-181
March 2023
European Society for Medical Oncology Targeted Anticancer Therapies (ESMO TAT) Congress
Safety and efficacy results of SRK-181 (a latent TGFβ1 inhibitor) from a phase 1 trial (DRAGON trial)
Fibrosis
Platform
November 2022
American College of Toxicology Annual Meeting 2022
Selective Latent TGFβ1 Inhibitors Exhibits Improved Nonclinical Safety Profile
Immuno-Oncology
SRK-181
November 2022
Poster Hall
SRK-181, a latent TGFβ1 inhibitor: safety, efficacy, and biomarker results from the dose escalation portion of a phase I trial (DRAGON trial) in patients with advanced solid tumors
Spinal Muscular Atrophy
Apitegromab
October 2022
International Scientific Congress on SMA
Apitegromab in SMA: Efficacy, Safety and PK/PD Assessments in 24 Months of TOPAZ
Spinal Muscular Atrophy
Apitegromab
October 2022
WMS Hybrid Congress
Apitegromab in SMA: An analysis of multiple efficacy endpoints in the TOPAZ extension study (P.102)
Immuno-Oncology
SRK-181
September 2022
12th Annual World Clinical Biomarkers & CDx Summit
